|4Oct 28, 5:42 PM ET

OPTIMER PHARMACEUTICALS INC 4

4 · OPTIMER PHARMACEUTICALS INC · Filed Oct 28, 2013

Insider Transaction Report

Form 4
Period: 2013-10-24
Gorbach MD Sherwood
SVP, Chief Medical Officer
Transactions
  • Disposition to Issuer

    Common stock

    2013-10-24$10.75/sh2,333$25,0800 total
  • Disposition to Issuer

    Stock option (right to buy)

    2013-10-24$11.70/sh11,610$135,8370 total
    Exercise: $1.08Exp: 2015-12-02Common stock (11,610 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-10-24$2.06/sh60,000$123,6000 total
    Exercise: $10.72Exp: 2023-02-26Common stock (60,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-10-24$11.70/sh1,298$15,1870 total
    Exercise: $1.08Exp: 2015-12-02Common stock (1,298 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-10-24$6.19/sh100,000$619,0000 total
    Exercise: $6.59Exp: 2018-03-12Common stock (100,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-10-24$3.75/sh20,000$75,0000 total
    Exercise: $9.03Exp: 2020-09-15Common stock (20,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-10-24$1.37/sh40,000$54,8000 total
    Exercise: $11.41Exp: 2021-01-26Common stock (40,000 underlying)
  • Disposition to Issuer

    Common stock

    2013-10-24$10.75/sh39,886$428,7752,333 total
  • Disposition to Issuer

    Stock option (right to buy)

    2013-10-24$5.88/sh7,500$44,1000 total
    Exercise: $6.90Exp: 2018-01-04Common stock (7,500 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-10-24$0.93/sh12,000$11,1600 total
    Exercise: $11.85Exp: 2020-01-08Common stock (12,000 underlying)
Footnotes (4)
  • [F1]Pursuant to the Agreement and Plan of Merger, dated as of July 30, 2013 (the "Merger Agreement"), among Optimer Pharmaceuticals, Inc. ("Optimer"), Cubist Pharmaceuticals, Inc. ("Cubist"), and PDRS Corporation, shares were converted into the right to receive per share consideration of: (i) $10.75 cash and (ii) one contingent value right issued by Cubist in accordance with the Contingent Value Rights Agreement, dated as of October 24, 2013, between Cubist and American Stock Transfer & Trust Company, LLC (together, the "Per Share Merger Consideration").
  • [F2]Pursuant to the terms of the Merger Agreement, each award was fully vested and converted into the right to receive the Per Share Merger Consideration with respect to each share of Optimer common stock subject to the award.
  • [F3]Pursuant to the terms of the Merger Agreement, each option was converted into the right to receive a cash payment equal to the excess, if any, of $12.78 (the last reported sale price of a share of Optimer common stock on The NASDAQ Global Select Market on October 23, 2013) over such option's per share exercise price.
  • [F4]Pursuant to the terms of the Merger Agreement, each option was fully vested and converted into the right to receive a cash payment equal to the excess, if any, of $12.78 (the last reported sale price of a share of Optimer common stock on The NASDAQ Global Select Market on October 23, 2013) over such option's per share exercise price.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT